https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-10-01 09:48:492026-10-01 09:48:49Hansa Biopharma Partners with Cradle to Advance AI-Driven Protein Design and Engineering
https://www.optimumcomms.com/wp-content/uploads/2025/09/DaltonTx.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-10-01 08:32:122026-10-01 08:32:12DaltonTx, the decision engine for drug discovery, launches advanced AI-powered antibody discovery platform
https://www.optimumcomms.com/wp-content/uploads/2026/09/numab-website-logo.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-10-01 08:31:312026-10-01 08:31:31Numab Therapeutics Appoints Dr. Rajesh Chopra as Chief Scientific Officer to Advance its Proprietary Multispecific Antibody Pipeline
https://www.optimumcomms.com/wp-content/uploads/2025/06/Atrogi_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-10-01 08:31:222026-10-01 08:31:22Atrogi announces positive human data for ATR-258, its first-in-class, oral therapy designed to improve muscle function and body composition
https://www.optimumcomms.com/wp-content/uploads/2026/03/Template_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-09-30 12:01:062026-09-30 12:01:06R1 Therapeutics expands Series A to $80.5 million to advance global Phase 2b program in hyperphosphatemia
https://www.optimumcomms.com/wp-content/uploads/2025/12/Oncoinvent_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-09-30 08:30:502026-09-30 08:30:50Oncoinvent to present three abstracts at EANM and ESMO 2026
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-09-29 08:48:462026-09-29 08:48:46Poolbeg Pharma plc – Interim Results for the six months to 30 June 2026
https://www.optimumcomms.com/wp-content/uploads/2026/09/Currus-website-logo.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-09-29 08:39:512026-09-29 08:58:31Currus Biologics announces FDA IND clearance for Phase 1 trial of CUR-001 in mesothelin-positive advanced refractory solid tumours
https://www.optimumcomms.com/wp-content/uploads/2025/06/Breye-logo.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-09-29 08:34:152026-09-29 08:34:15Breye Therapeutics raises €67.5 million in over-subscribed Series A financing
https://www.optimumcomms.com/wp-content/uploads/2026/06/Kither_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-09-29 08:30:132026-09-29 08:30:37Kither Biotech Initiates Dosing of Patients in Phase 1b / 2a Study of KIT2014 in COPD
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-09-28 07:55:252026-10-01 15:01:48Poolbeg Pharma – POLB 001 TOPICAL trial recruitment update
https://www.optimumcomms.com/wp-content/uploads/2023/02/Sofinnova_Logo_300-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-09-28 07:01:582026-09-28 07:04:58Sofinnova Partners closes oversubscribed €82 million Sofinnova MD Start IV fund to create the next generation of medtech companies
https://www.optimumcomms.com/wp-content/uploads/2023/02/Neuraxpharm_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-09-25 08:00:552026-09-25 08:00:55European Commission grants marketing authorisation for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-09-24 09:10:562026-09-24 09:10:56Hansa Biopharma Announces New Board Appointments
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-09-24 09:07:212026-09-24 09:07:21Interim data from POLB 001 TOPICAL clinical trial
https://www.optimumcomms.com/wp-content/uploads/2026/02/BOOSTPharma_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-09-24 08:32:442026-09-24 12:03:33BOOST Pharma Selected to Showcase Phase III Ready Lead Program BT-101 at the 2026 Cell & Gene Meeting on the Mesa
https://www.optimumcomms.com/wp-content/uploads/2025/01/Ona_Therapeutics_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-09-24 08:30:212026-09-24 08:30:21Ona Therapeutics advances as a clinical-stage company and appoints Aleix Prat, MD, PhD, as Chief Medical Officer
https://www.optimumcomms.com/wp-content/uploads/2025/06/Breye-logo.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-09-23 19:00:042026-09-23 17:20:32Breye Therapeutics has a paper on its oral danegaptide treatment for patients with NPDR published in Science Translational Medicine
https://www.optimumcomms.com/wp-content/uploads/2026/07/AC-Immune-website-logo.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-09-23 12:04:482026-09-23 12:04:48AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104
https://www.optimumcomms.com/wp-content/uploads/2026/09/Anaconda-biomed-logo-blue.png
130
606
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-09-23 08:41:332026-09-23 12:56:39Anaconda Biomed Secures $56 Million Financing from New and Existing InvestorsFor more information about Optimum Strategic Communications, please get in touch.
